NEXILICO, INC.
Albany, CA · Biotech · Private
computational platform for designing and discovering microbiome therapeutics by predicting microbial strain efficacy
- Grants
- $2.7M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A Predictive Computational Platform for Gut Microbiome Precision Medicine | $224,929 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: An omics-based computational platform for the personalization of gut microbiome therapeutics | $224,995 | |
| Federal grant | Department of Health and Human Services · Phase I · Computational prediction of gut microbiome-mediated drug metabolism | $325,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Computational prediction of gut microbiome-mediated drug metabolism | $55,000 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II:An omics-based computational drug design and discovery platform for next generation microbiome therapeutics | $1,623,498 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel probiotics to mitigate xenobiotic toxicity through microbial biotransformation | $275,765 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2553 | Venn Therapeutics, LLC | — | — |
| 2554 | Kovina Therapeutics Inc. | — | $2.0M |
| 2555 | CUROVERSE, INC. | — | $2.0M |
| 2556 | NEXILICO, INC. | — | — |
| 2557 | Hennepin Life Sciences | — | $1.9M |
| 2558 | Biomakers, Inc. | — | $1.5M |
| 2559 | Resilience Therapeutics, Inc. | — | $1.4M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.